David Gentien
Overview
Explore the profile of David Gentien including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
3051
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Delaloge S, Dureau S, DHondt V, Desmoulins I, Heudel P, Duhoux F, et al.
Eur J Cancer
. 2022 Mar;
166:300-308.
PMID: 35337692
Background: Besides their development as additional adjuvant treatments, CDK4/6 inhibitors combined with endocrine therapy could represent less toxic alternatives to chemotherapy in postmenopausal women with high-risk oestrogen receptor-positive, HER2-negative breast...
12.
Zeng Q, Klein C, Caruso S, Maille P, Laleh N, Sommacale D, et al.
J Hepatol
. 2022 Feb;
77(1):116-127.
PMID: 35143898
Background & Aims: Patients with hepatocellular carcinoma (HCC) displaying overexpression of immune gene signatures are likely to be more sensitive to immunotherapy, however, the use of such signatures in clinical...
13.
Suresh S, Huard S, Brisson A, Nemati F, Dakroub R, Poulard C, et al.
Cancers (Basel)
. 2022 Jan;
14(2).
PMID: 35053470
Identifying new therapeutic strategies for triple-negative breast cancer (TNBC) patients is a priority as these patients are highly prone to relapse after chemotherapy. Here, we found that protein arginine methyltransferase...
14.
Saghatchian M, Abehsera M, Yamgnane A, Geyl C, Gauthier E, Helin V, et al.
Breast Cancer Res Treat
. 2022 Jan;
192(2):375-383.
PMID: 34994879
Purpose: A personalized approach to prevention and early detection based on known risk factors should contribute to early diagnosis and treatment of breast cancer. We initiated a risk assessment clinic...
15.
Nguyen C, Caruso S, Maille P, Beaufrere A, Augustin J, Favre L, et al.
Clin Cancer Res
. 2021 Nov;
28(3):540-551.
PMID: 34785581
Purpose: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare malignancy associated with an overall poor prognosis. We aimed to investigate the immune profile of cHCC-CCA and determine its impact on disease outcome....
16.
Sirab N, Drubay D, Maille P, Popova T, Ngo C, Gentien D, et al.
J Pathol
. 2021 Oct;
256(1):108-118.
PMID: 34611919
Basal/squamous (Ba/Sq) subtype represents an intrinsic and robust group in the consensus molecular classification of muscle-invasive bladder cancer (MIBC), with poor outcome and controversial chemosensitivity. We aimed to investigate the...
17.
Liu J, Ottaviani D, Sefta M, Desbrousses C, Chapeaublanc E, Aschero R, et al.
Nat Commun
. 2021 Sep;
12(1):5578.
PMID: 34552068
Retinoblastoma is the most frequent intraocular malignancy in children, originating from a maturing cone precursor in the developing retina. Little is known on the molecular basis underlying the biological and...
18.
Bieche I, Coussy F, El-Botty R, Vacher S, Chateau-Joubert S, Dahmani A, et al.
J Hematol Oncol
. 2021 Sep;
14(1):143.
PMID: 34496925
Malignant adenomyoepithelioma (AME) of the breast is an exceptionally rare form of breast cancer, with a significant metastatic potential. Chemotherapy has been used in the management of advanced AME patients,...
19.
Malapelle U, Pepe F, Pisapia P, Altimari A, Bellevicine C, Brunnstrom H, et al.
J Clin Pathol
. 2021 Aug;
76(1):47-52.
PMID: 34429353
Aims: Gene fusions assays are key for personalised treatments of advanced human cancers. Their implementation on cytological material requires a preliminary validation that may make use of cell line slides...
20.
Marisa L, Blum Y, Taieb J, Ayadi M, Pilati C, Le Malicot K, et al.
Clin Cancer Res
. 2021 Jun;
27(17):4768-4780.
PMID: 34168047
Purpose: The consensus molecular subtypes (CMS) represent a significant advance in the understanding of intertumor heterogeneity in colon cancer. Intratumor heterogeneity (ITH) is the new frontier for refining prognostication and...